Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galapagos NV filings document foreign-issuer disclosures made primarily on Form 6-K, including material events, shareholder meeting results, governance actions, capital-structure updates and clinical or regulatory communications. The records cover annual and extraordinary meeting votes, remuneration and board matters, subscription right plans, registration-statement incorporation, and transparency notifications under Belgian ownership-disclosure rules.
The company’s filings also include press releases and corporate presentations related to strategic collaborations, T cell engager and cell-therapy programs, operating and financial results, and shareholder voting mechanics. For this ADR-listed biotechnology issuer, the filing record ties business development, pipeline disclosures, ownership thresholds, employee equity instruments and corporate-governance approvals to formal U.S. securities reporting.
Galapagos NV (ticker: GLPG) filed a routine Form 6-K with the U.S. SEC for the month of June 2025. The filing primarily serves to furnish a press release dated 23 June 2025 (attached as Exhibit 99.1) and to incorporate that exhibit—excluding quotations from Henry Gosebruch and Aaron Cox—into the company’s numerous Form S-8 registration statements (File Nos. 333-204567 through 333-283361). No financial statements, earnings data, or major transactional information are included in the submission. The document was signed on 25 June 2025 by Company Secretary Annelies Denecker.
Because the 6-K contains no new material metrics or strategic disclosures, it appears to be a standard compliance filing intended to keep investors informed and maintain the legal effectiveness of existing employee equity plans registered on Form S-8.
Galapagos NV (ticker: GLPG) filed a Form 6-K on 20 June 2025. The submission is primarily administrative in nature. It:
- Announces that a press release dated 18 June 2025 is furnished as Exhibit 99.1.
- States that the information in the report—excluding specific physician quotations in the exhibit—is incorporated by reference into multiple outstanding Form S-8 registration statements.
- Contains no financial statements, earnings metrics, or details on material transactions.
- Is signed by Company Secretary Annelies Denecker.